"The initiation of a Phase IIb trial in pancreatic cancer midyear is one of a number of studies in patients with solid tumors that we're considering. Pancreatic cancer is particularly interesting as there is an obvious high therapeutic need evidenced by a relative lack of efficacy with existing agents. In this regard, 424 works quite well in preclinical models of pancreatic cancer. In addition since there is a high incidence of severe cachexia in this patient group, we think our very positive results from cachexia in myelofibrosis have the potential to be carried over to pancreatic cancer since a cytokine over-signaling and hypercatabolism are thought to play major roles in solid tumor cachexias as well."
Not so sure. Science Daily reported yesterday that scientists at Oklahoma Cancer Center found that Gefitinib, and FDA approved drug appears to be very successful when used for early stages of Pancreatic cancer. They project phase II studies later this year.